NVSEF - Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)
2025-10-13 14:35:33 ET
Shares of mast cell therapy concern Celldex Therapeutics, Inc. ( CLDX ) have rallied just over 70% off their 60-month April 2025 low that was caused by high discontinuation rates for lead asset barzolvolimab. The company’s only significant candidate has demonstrated best-in-class efficacy in chronic spontaneous urticaria, which it is trying to replicate in two Phase 3 studies that are now enrolling. With an operating runway through 2027, good enough to get it through four needle-moving studies in increasingly competitive indications, Celldex merited a deeper dive. An analysis follows below....
Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)